As per the research report, the size of the Asia Pacific Biopharmaceutical Contract Manufacturing market is valued at USD 1.38 billion in 2021. It is expected to rise at a CAGR of 9.38% and expand to USD 2.16 billion by 2026.
A contract manufacturing organization (CMO) is a company that provides complete services from drug discovery to drug manufacturing to other companies in the biopharmaceutical industry on a contract basis.
One of the most important factors is that large biopharmaceuticals differ from small pharmaceutical molecules in size, behavior, manufacturing, and how they function in the human body. In addition, making such giant molecules is a lot more complicated than making typical medications.
Furthermore, biopharma is a highly technological business with numerous complex procedures that only a few players have mastered. Biopharmaceutical businesses have been increasing in size for some years, and large pipeline compounds in clinical trials suggest that this trend will continue.
Another factor driving the market is the decision of major biopharmaceutical companies to outsource specific portions of their operations, which can help with scalability or let the significant company concentrate on drug discovery and marketing. Biotechnology companies continue to outsource to contract manufacturing organizations (CMOS) to meet their fill-and-finish demands and decrease risk.
In the biopharmaceuticals contract manufacturing business, government backing is becoming increasingly important. As a result, the biopharmaceuticals contract manufacturing market's players heavily rely on this factor. In addition, in the biopharmaceuticals contract manufacturing industry, the adoption of cutting-edge strategies to generate high-performance medications is gaining traction.
Furthermore, as the biopharmaceutical business grows, companies are encountering production challenges such as a lack of experience and sophisticated equipment when using in-house manufacturing.
On the other hand, large-scale companies see outsourcing as risky due to the loss of strategic control and management oversight. As a result, big pharmaceutical corporations prefer to keep their manufacturing processes in-house. To some extent, this is projected to provide a hurdle to the rise of CMOS.
This research report on the APAC Biopharmaceutical Contract Manufacturing Market has been segmented and sub-segmented into the following categories:
By Product Type:
By Therapeutic Area:
Geographically, the APAC region is the fastest-growing biopharmaceuticals contract manufacturing market, owing to many biopharmaceutical companies with significant production capacity and the increasing consumption of biologics in this region.
Furthermore, the growing emphasis on superior biopharmaceutical products, biosimilars, and biopharmaceutical-based research and development activities accounted for a significant percentage of weightage carried out in various sectors, fueling the overall regional market growth to a large extent.
Asia Pacific may emerge as a growth hub for the biopharmaceuticals contract manufacturing market. Increased research and development could be a significant growth driver for the biopharmaceuticals contract manufacturing industry.
Furthermore, biopharmaceuticals contract manufacturing market manufacturers are expanding their production facilities to facilitate large-scale drug and vaccine production in the region.
Due to lower operating and production costs given by nations like India and China, Asia Pacific could play a significant role in the biopharmaceuticals contract manufacturing market.
KEY MARKET PLAYERS
The Top companies leading in the APAC Biopharmaceutical contract manufacturing market profiled in the report are Lonza Group AG, Baxter Biopharma Solutions, Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, Boehringer Ingelheim GmbH, Patheon N.V., Rentschler Biotechnologie GmbH, Biomeva GmbH, Probiogen AG, Cytovance Biologics, Inc., KBI Biopharma, Inc., WuXi Biologics, Abzena Plc, Vetter Pharma International GmbH, Sandoz International GmbH, Catalent, Inc., AbbVie Contract Manufacturing (An AbbVie Company), Ajinomoto Althea Inc.,
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product Type
5.1.3 Monoclonal Antibodies
5.1.4 Growth Factors
5.1.6 Recombinant Protiens
5.1.9 Y-o-Y Growth Analysis, By Product Type
5.1.10 Market Attractiveness Analysis, By Product Type
5.1.11 Market Share Analysis, By Product Type
5.2 Therapeutic Area
5.2.2 Infectious Disease
5.2.5 Metabolic Disease
5.2.6 Respiratory Disorder
5.2.7 Autoimmune Disease
5.2.11 Y-o-Y Growth Analysis, By Therapeutic Area
5.2.12 Market Attractiveness Analysis, By Therapeutic Area
5.2.13 Market Share Analysis, By Therapeutic Area
5.3.4 Y-o-Y Growth Analysis, By Application
5.3.5 Market Attractiveness Analysis, By Application
5.3.6 Market Share Analysis, By Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product Type
184.108.40.206 By Therapeutic Area
220.127.116.11 By Application
6.1.4 Market Attractiveness Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product Type
126.96.36.199 By Therapeutic Area
188.8.131.52 By Application
6.1.5 Market Share Analysis
184.108.40.206 By Geographical Area
220.127.116.11 By Product Type
18.104.22.168 By Therapeutic Area
22.214.171.124 By Application
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Patheon N.V.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2Rentschler Biotechnologie GmbH
8.3 AbbVie Contract Manufacturing (An AbbVie Company)
8.4 Biomeva GmbH
8.5 Boehringer Ingelheim GmbH
8.6 WuXi Biologics
8.7 Abzena Plc
8.8 Lonza Group AG
8.9 Samsung Biologics Co.
8.10 Ajinomoto Althea, Inc.
8.11 Fujifilm Diosynth Biotechnologies
8.12 Probiogen AG
8.13 Sandoz International GmbH
8.14 KBI Biopharma, Inc.
8.15 Baxter Biopharma Solutions
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures